Abiraterone Acetate clinical trials
Also written Zytiga, CB7630, Yonsa and JNJ-212082.
A product of Abiraterone; its studies count on that page too.
Counted the way a researcher would: Abiraterone Acetate with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Abiraterone Acetate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Abiraterone Acetate studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Apr 2011 · ZYTIGA · NDA 202379 (FDA, Drugs@FDA)
- European Union
- 5 Sept 2011 · Zytiga · EMEA/H/C/002321 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
127 studies that test it; most in 2020 (13)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 4 |
| 2008 | 2 |
| 2009 | 5 |
| 2010 | 4 |
| 2011 | 8 |
| 2012 | 11 |
| 2013 | 12 |
| 2014 | 11 |
| 2015 | 5 |
| 2016 | 7 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 13 |
| 2021 | 8 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 49 · Other 78
Janssen Research & Development, LLC (21) · Cougar Biotechnology, Inc. (9) · M.D. Anderson Cancer Center (6) · University of Washington (4) · Dana-Farber Cancer Institute (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Sun Pharmaceutical Industries Limited (3) · Mayo Clinic (2)
Often tested with
Tested in the same studies.
Prednisone (27) · Apalutamide (13) · Enzalutamide (13) · Niraparib (6) · Prednisolone (5) · Leuprolide (4) · Cabazitaxel (4) · Docetaxel (4)
Related medicines
As reviewed, each with the page that says it.
- A salt or form of Abiraterone
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 4 phase 3 studies under way
Abiraterone Acetate is the comparator. A study of two new drugs counts under both.
- 2Opevesostat · Merck Sharp & Dohme LLC · next primary completion May 2028
- 1Cabozantinib · Exelixis
- 1Atezolizumab · Exelixis
- 1Darolutamide · ECOG-ACRIN Cancer Research Group · next primary completion Mar 2029
Reaching primary completion within a year · 8, 1 in phase 3
Studies that test Abiraterone Acetate, phase 3 first.
- Dec 2026ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerPhase 3 · Karolinska Institutet
- Dec 2026Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerPhase 2 · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Jan 2027Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate CancerPhase 2 · Jonsson Comprehensive Cancer Center
- Feb 2027Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate CancerPhase 2 · M.D. Anderson Cancer Center
- May 2027A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate CancerPhase 1/2 · University of Michigan Rogel Cancer Center
- Jun 2027Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerPhase 2 · University of British Columbia
- Aug 2027Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerPhase 2 · City of Hope Medical Center
- Oct 2027Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)Phase 1/2 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses Abiraterone Acetate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 127
- Targeted Treatment for Metastatic Prostate Cancer, The PREDICT TrialRecruitingPhase 2Alliance for Clinical Trials in OncologyNCT06632977Written as Abiraterone Acetate
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingPhase 2VA Office of Research and DevelopmentNCT05593497Written as abiraterone acetate
- Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE TrialRecruitingPhase 2Mayo ClinicNCT07650240Written as Abiraterone Acetate
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingPhase 2University of British ColumbiaNCT04812366Written as Abiraterone Acetate 250mg
- Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients.RecruitingPhase 2Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología RadioterápicNCT07717268Written as Zytiga® (Abiraterone Acetate)
- Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC StudyRecruitingPhase 2University of WashingtonNCT04175431Written as Abiraterone Acetate
- Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.RecruitingPhase 2Sun Pharmaceutical Industries LimitedNCT05422911Written as Abiraterone acetate
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerRecruitingPhase 2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT06616597Written as Abiraterone acetate
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingPhase 2City of Hope Medical CenterNCT04734730Written as Abiraterone Acetate
- Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate CancerRecruitingPhase 2Martha MimsNCT03833921Written as Abiraterone Acetate
- Determining the Effect of Abiraterone on the Metabolism of Oxycodone in Men With Prostate Cancer (the ENABLE Study)RecruitingPhase 4Deventer ZiekenhuisNCT07001709Written as Abiraterone Acetate Tablets 500 mg
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingPhase 3Karolinska InstitutetNCT03903835Written as Niraparib plus Abiraterone acetate plus Prednisone
- Phase III Study of Abiraterone Acetate (II) Versus Abiraterone Acetate in Patients with MCRPCNot yet recruitingPhase 3Ding-Wei YeNCT06768255Written as Abiraterone Acetate (II)+ prednisolone (5mg bid) +ADT
- Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)Not yet recruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT06099990Written as dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT05406999Written as Abiraterone Acetate
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT04497844Written as Niraparib+ Abiraterone acetate fixed dose combination (FDC)
- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 1Aragon Pharmaceuticals, Inc.NCT02123758Written as Abiraterone Acetate
- A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerActive, not recruitingPhase 3Janssen Research & Development, LLCNCT03748641Written as Abiraterone Acetate
- A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04577833Written as Abiraterone Acetate (AA)
- Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate CancerActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03821792Written as Abiraterone Acetate
See all 127 studies that test Abiraterone Acetate →
Given beside what is tested · 60 — Abiraterone Acetate is usual care or a partner of the new treatment
- A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate CancerRecruitingPhase 1Janssen Research & Development, LLCNCT05818683Written as Abiraterone acetate plus prednisone (AAP)
- MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)Not yet recruitingPhase 1/2Merck Sharp & Dohme LLCNCT07908524Written as Abiraterone acetate
- A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate CancerRecruitingPhase 3AmgenNCT07213674Written as Abiraterone acetate
- Study of ORIC-944 in Patients With Metastatic Prostate CancerRecruitingPhase 1ORIC PharmaceuticalsNCT05413421Written as Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
- A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT06457919Written as abiraterone acetate with prednisone
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingPhase 2M.D. Anderson Cancer CenterNCT04947254Written as Abiraterone Acetate
- A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07198633Written as abiraterone acetate
- REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialRecruitingPhase 3Emory UniversityNCT06650579Written as Abiraterone Acetate
- Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate CancerNot yet recruitingPhase 1/2Qilu Pharmaceutical Co., Ltd.NCT07104110Written as abiraterone acetate
- Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPCRecruitingPhase 2Leiden University Medical CenterNCT05393791Written as Abiraterone acetate
- Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.Not yet recruitingPhase 2Qilu Hospital of Shandong UniversityNCT06500247Written as Abiraterone Acetate (II)
- Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive, not recruitingPhase 3AstraZenecaNCT06120491Written as Abiraterone Acetate
- A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate CancerCompletedPhase 3Alliance Foundation Trials, LLC.NCT03009981Written as Abiraterone Acetate
- An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)Active, not recruitingPhase 3Aragon Pharmaceuticals, Inc.NCT02257736Written as Abiraterone acetate
- ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate CancerActive, not recruitingPhase 1Janssen Research & Development, LLCNCT04662580Written as Abiraterone acetate
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyActive, not recruitingPhase 2Astellas Pharma Global Development, Inc.NCT02960022Written as abiraterone acetate
- Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With DocetaxelActive, not recruitingPhase 2ECOG-ACRIN Cancer Research GroupNCT03419234Written as Abiraterone Acetate
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2Janssen Research & Development, LLCNCT03431350Written as Abiraterone acetate 1000 mg
- Study to Evaluate CCS1477 in Advanced TumoursCompletedPhase 1/2CellCentric Ltd.NCT03568656Written as Abiraterone acetate
- Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyActive, not recruitingPhase 3AstraZenecaNCT04493853Written as Abiraterone Acetate
Showing 20 of 60.
As the comparator · 12 — what is tested is compared with Abiraterone Acetate
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136624Written as Abiraterone acetate
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06136650Written as Abiraterone acetate
- Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate CancerNot yet recruitingPhase 2/3ECOG-ACRIN Cancer Research GroupNCT07852195Written as Abiraterone Acetate
- A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerRecruitingPhase 2Astellas Pharma Global Development, Inc.NCT07005154Written as abiraterone acetate
- Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)RecruitingPhase 1Jiangsu HengRui Medicine Co., Ltd.NCT05942001Written as Abiraterone acetate tablets
- Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing SurgeryActive, not recruitingPhase 2Rutgers, The State University of New JerseyNCT02949284Written as Abiraterone Acetate
- Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 MutationsActive, not recruitingPhase 4AstraZenecaNCT05457257Written as abiraterone acetate
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingPhase 3ExelixisNCT04446117Written as Abiraterone Acetate
- Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)CompletedPhase 3Merck Sharp & Dohme LLCNCT03834519Written as Abiraterone acetate
- TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate CancerCompletedPhase 3Tavanta TherapeuticsNCT04887506Written as Zytiga
- Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)CompletedPhase 3AstraZenecaNCT02987543Written as abiraterone acetate
- Cabazitaxel Versus the Switch to Alternative AR Targeted Therapy Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Primary Resistant Patients to Abiraterone or EnzalutamideTerminatedPhase 2SanofiNCT02379390Written as Abiraterone acetate
Codes
What other systems call Abiraterone Acetate · ClinicalTrials.gg INT006603
- MeSH (NLM) D000069501Abiraterone AcetateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) EM5OCB9YJ6ABIRATERONE ACETATEConfirmed FDA, NLM, Wikidata
- RxNorm 1100071Confirmed FDA, Wikidata
- Wikidata Q27888393abiraterone acetateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C68845Abiraterone AcetateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069501 | Abiraterone Acetate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | EM5OCB9YJ6 | ABIRATERONE ACETATE | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1100071 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27888393 | abiraterone acetate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C68845 | Abiraterone Acetate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.